Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Serial assays of blood coagulation factors as well as of fibrin/fibrinogen degradation products (FDP) and plasminogen activatory activity (PA) on fibrin plates in blood and cerebrospinal fluid (CSF) were performed in 41 consecutive patients with recently ruptured cerebral aneurysms, 21 of whom were randomly treated with tranexamic acid (AMCA). Coagulation factors were unaffected by the drug and plasminogen and FDP decreased in blood after two weeks' treatment. After one week, PA in CSF was increased in control patients and unchanged in AMCA-treated patients, whereas CSF-FDP had decreased among AMCA-treated patients. After two weeks PA as well as FDP in CSF showed the same values in both groups. An increase in CSF-FDP occurred after rebleeding and in patients with cerebral ischaemic symptoms. The results indicate that AMCA inhibits local fibrinolysis in CSF in patients with aneurysm rupture.
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis / Q000134:cerebrospinal fluid; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000097:blood / Q000134:cerebrospinal fluid; D013345:Subarachnoid Hemorrhage / Q000097:blood* / Q000134:cerebrospinal fluid / Q000188:drug therapy; D014148:Tranexamic Acid / Q000494:pharmacology / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D005338:Fibrin Fibrinogen Degradation Products; D014148:Tranexamic Acid; D010960:Plasminogen Activators